2030 Biosimilars Compounding 
Express Pharma
JANUARY 11, 2024
The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8 Canakinumb, set for a 2030 launch, is a biosimilar to the established Ilaris therapy. per cent from $4.6 billion in 2022 to $10.8
European Pharmaceutical Review
APRIL 3, 2024
Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 percent between 2022-2030. percent between 2022-2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
OCTOBER 16, 2024
The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 billion by 2030 (2). Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally. per cent, is projected to reach $2.5 per cent, hitting $44.63
Express Pharma
MAY 13, 2025
The report analyses 11 initiatives that have been specifically established to provide diabetes care for CYP, which are varyingly backed by major insulin producers Lilly, Novo Nordisk and Sanofi, as well as biosimilar insulin manufacturer Biocon. CYP’s access to long-term, affordable diabetes care remains a critical challenge.
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
Safe Biologics
JUNE 12, 2023
Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).
Pharmacy Times
JUNE 19, 2025
With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.
Expert insights. Personalized for you.
103 
Let's personalize your content